Onconova Therapeutics announced two presentations relating to clinical trials of its most advanced product candidate, rigosertib, at the 55th American Society of Hematology Annual Meeting in New Orleans, Louisiana, December 7-10. The presentations included data on efficacy, tolerability, and dosing regimen from the Phase 2 ONTARGET study of oral rigosertib in transfusion-dependent, lower risk MDS patients and response, overall survival, and longer-term follow-up data from a Phase 1/2 trial of intravenous rigosertib in higher risk post-hypomethylating agent-treated MDS and acute myeloid leukemia patients. "The presentations at ASH reinforce the emerging therapeutic and safety/tolerability profiles of rigosertib, our small-molecule inhibitor of PI3K and PLK pathways, and underscore our commitment to develop rigosertib as a novel treatment for patients with MDS. We look forward to the design of an approval-track trial of oral rigosertib in transfusion-dependent, lower risk MDS and top-line data from our Phase 3 pivotal trial in higher risk MDS," the company said.